CTMX Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - CytomX Therapeutics Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 4.43 USD -1.56%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast CTMX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 2.96 USD with a low forecast of 2.27 USD and a high forecast of 3.68 USD.

CTMX Lowest Forecast

Wall Street Target

CTMX Average Forecast

Wall Street Target

CTMX Highest Forecast

Wall Street Target

49% Downside

33% Downside

17% Downside

The latest public price target was made on Mar 12, 2024 by Roger Song from Jefferies , who expects CTMX stock to drop by 44% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Roger Song Jefferies	2.5 USD Downside 44%	1 month ago Mar 12, 2024	CytomX Therapeutics (CTMX) PT Raised to $2.50 at Jefferies, 'EGFRxCD3 on Track for Ph1a Data in 2H24' StreetInsider
Etzer Darout BMO Capital	3.25 USD Downside 27%	1 month ago Mar 12, 2024	CytomX Therapeutics (CTMX) PT Lowered to $3.25 at BMO Capital, 'Pipeline Updates Broadly in Line' StreetInsider

Price Target	2.5 USD
Upside/Downside	44%

Price Target	3.25 USD
Upside/Downside	27%

KeyMed Biosciences Inc

74% Upside

Bioporto A/S

286% Upside

Genfit SA

193% Upside

Sinocelltech Group Ltd

41% Upside

KeyMed Biosciences Inc

74% Upside

Bioporto A/S

286% Upside

Genfit SA

193% Upside

Sinocelltech Group Ltd

41% Upside

Moderna Inc

8% Upside

Pharming Group NV

107% Upside

Ascletis Pharma Inc

114% Upside

Gilead Sciences Inc

30% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 38%. The projected CAGR for the next 3 years is -23%.

38%

-23%

-1%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

-1%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-48%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for CTMX is 2.96 USD with a low forecast of 2.27 USD and a high forecast of 3.68 USD.

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 38%. The projected CAGR for the next 3 years is -23%.

Join more than 134,500+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.